

## For immediate release

Lure, France October 5th, 2017

## MONTHLY INFORMATION REGARDING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING OF THE SHARE CAPITAL

as per article 223.16 of the « Règlement Général de « L'Autorité des Marchés Financiers »

| Date       | Previous<br>total number<br>of shares<br>making of<br>the share<br>capital | Previous total<br>number of<br>voting rights | Change<br>explanation                         | New total<br>number of<br>shares making<br>of the share | New total<br>number of<br>voting rights |
|------------|--|--|---|---|---|
| 30/09/2017 | 11.881.902   | 20.490.290                                   | Fluctuation in the<br>double voting<br>rights | 11.881.902  | 20.489.797                              |

## **About Vetoquinol**

Vetoquinol is a leading global player in the animal health sector serving both the livestock (cattle and pigs) and pet (dogs and cats) markets.

A family owned, pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.

Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. Vetoquinol employs 2.000 people world-wide.

Vetoquinol has been listed on NYSE Euronext Paris since 2006 (symbol: VETO).

For more information: www.vetoquinol.com.

**VETOQUINOL** 

Fanny TOILLON relations.investisseurs@vetoquinol.com